ANI PHARMACEUTICALS, INC Operating Lease Liability
ANI PHARMACEUTICALS, INC (ANIP) had Operating Lease Liability of $11.10 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-27
- 2025-12-31: Operating Lease, Liability $11.10M.
- 2025-09-30: Operating Lease, Liability $5.20M.
- 2025-08-18: Operating Lease, Liability $5.20M.
- 2024-12-31: Operating Lease, Liability $6.19M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $11.10M 10-K · filed 2026-02-27 |
| 2025-09-30 | $5.20M 10-Q · filed 2025-11-07 |
| 2025-08-18 | $5.20M 10-K · filed 2026-02-27 |
| 2024-12-31 | $6.19M 10-K · filed 2025-02-28 |
| 2023-12-31 | $5.67M 10-K · filed 2024-02-29 |
| 2022-12-31 | $2.06M 10-K · filed 2023-03-09 |
| 2022-09-30 | $2.08M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.41M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.28M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.38M 10-K · filed 2022-03-15 |
| 2021-09-30 | $320.00K 10-Q · filed 2021-11-01 |
| 2021-06-30 | $351.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $382.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | $301.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $430.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $483.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $440.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $489.00K 10-K · filed 2020-02-27 |
| 2019-09-30 | $483.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $527.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $546.00K 10-Q · filed 2019-05-09 |
| 2019-01-31 | $500.00K 10-Q · filed 2019-11-06 |
| 2019-01-01 | $500.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |